ENDRA Life Sciences Initiates Review of Strategic Alternatives to Maximize Shareholder Value

Stock Information for ENDRA Life Sciences Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About ENDRA Life Sciences Inc.

ENDRA Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
ENDRA's TAEUS® Liver Device Demonstrates High-Level Consistency in Clinical Study, Delivering MRI-Level Results at the Point of Patient Care
ENDRA's TAEUS® Liver Matches MRI-PDFF Performance at Key Clinical Thresholds, Positioning Device for MASLD/MASH Trial Use
ENDRA Feasibility Study Demonstrates TAEUS® Accurately Quantifies Liver Fat Fraction, a Key MASLD/MASH Biomarker
ENDRA Life Sciences Recaps Major Milestones and New Strategic Initiatives, Announces Third Quarter 2025 Financial Results
ENDRA Life Sciences Commences Staking of HYPE Digital Asset Holdings, Reinforcing Long-Term Strategy with Anchorage Digital and ARCA
ENDRA Life Sciences Closes Up to $14.4 Million Private Placement and Launches Crypto Treasury Strategy with $3 Million in Initial HYPE Token Holdings
ENDRA Life Sciences Announces At-Market Private Placement of Up to $14.4 Million to Launch Digital Asset Treasury Strategy Managed by Leading Crypto Asset Manager Arca

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.